Arrow
Arrow
Slider

Premaitha Health PLC
(“Premaitha” or the “Company”)

Premaitha Raises Awareness of the IONA® Test at Key International Medical Events

Manchester, UK – 13 March 2017: Premaitha Health PLC (AIM: NIPT), a leading international molecular diagnostics group focused on prenatal testing, will be attending a series of key international fetal medicine and OB/GYN events during March to broaden awareness of the IONA® test. The events will include:

The Royal College of Obstetricians and Gynaecologists (RCOG) World Congress 2017

The RCOG World Congress 2017 will be held in Cape Town, South Africa between 20 - 22 March 2017. Premaitha will host an exhibition booth showcasing the IONA® test to a large number of obstetrician and gynaecologist professionals from around the world. For further details, visit: www.rcog2017.com.

Forum Labo

Forum Labo will be held in Paris, France between 28 - 30 March 2017. Executives from Premaitha will attend this event together with the Company’s French distributor, Adgenix, to promote the benefits of the IONA® test to the large number of laboratory professionals from France that will be in attendance. For further details, visit: www.forumlabo.com.

The British Maternal and Fetal Medicine Society (BMFMS), 19th Annual Conference

The BMFMS 19th Annual Conference will be held in Amsterdam, The Netherlands between 30 – 31 March 2017. As a Gold Sponsor, Premaitha will have a significant presence at the event, hosting an exhibition booth and an educational symposium on non-invasive prenatal screening. The delegates will hear from three key opinion leaders – who are also Premaitha customers - discussing different topics relating to the IONA® test. The speakers will include leading obstetricians:
•    Dr Asma Khalil from St George’s NHS Hospital;
•    Dr Francois Jacquemard from the American Hospital in Paris; and
•    Dr Kelly Cohen from Leeds NHS Teaching Hospital Trust.

In addition, there will be two clinical posters presented by two further IONA® test clinicians from the UK. For further details, visit: www.bmfmsconference.ukevents.org.

The 7th Congress of the Asia Pacific Initiative on Reproduction (ASPIRE)

ASPIRE 2017 will be held in Kuala Lumpur, Malaysia between 30 March – 2 April 2017. Premaitha will host an exhibition booth in partnership with the Company’s Malaysian distributor, Analisa Scientific, showcasing the IONA® test to the region’s clinicians, nurses, researchers and academics operating in the field of reproductive medicine and fertility. For further details, visit: www.aspire2017.com.

Dr Stephen Little, CEO of Premaitha Health, commented: “Raising awareness of the superiority of the IONA® test among the international OB/GYN community is key to helping drive samples to our customers’ laboratories. March is expected to be a very busy month in the ongoing educational programme.”

For more information, please contact:

Premaitha Health PLC    
Dr Stephen Little, Chief Executive Officer    
Barry Hextall, Chief Financial Officer    
This email address is being protected from spambots. You need JavaScript enabled to view it.
Tel: +44 (0) 161 667 6865
    
Vigo Communications    
Ben Simons / Fiona Henson / Antonia Pollock    
This email address is being protected from spambots. You need JavaScript enabled to view it.
Tel: +44 (0) 20 7830 9700

About Premaitha

Premaitha is an international molecular diagnostics group which uses the latest advances in DNA analysis technology to develop safer, faster and regulatory approved genetic screening tests. The Group’s primary focus is on non-invasive prenatal tests (NIPT) for pregnant women - an emerging, multi-billion dollar global market.

Premaitha’s IONA® test was launched in 2015 as the first CE-IVD NIPT test in Europe. It enables laboratories and healthcare practitioners to offer a complete CE-marked NIPT system in-house. The IONA® test is performed on a maternal blood sample – which contains traces of fetal DNA – and estimates the risk of a fetus being affected with Down’s syndrome or other genetic conditions.

Unlike existing prenatal screening methods, due to its high level of accuracy, the IONA® test can significantly reduce the number of women subjected to unnecessary invasive follow up diagnostic procedures, such as amniocentesis, which are costly, resource intensive and carry a risk of miscarriage.

In March 2017, Premaitha acquired Yourgene Bioscience, a specialist next generation sequencing and bioinformatics company based in Taiwan, with its own NIPT screening test that operates on the same Thermo Fisher next-generation sequencing platform as Premaitha’s IONA® test. Yourgene brings significant benefits to the Group through expanded market access in Asia – the world's fastest growing NIPT market – as well as opportunities for cross-selling and the ability to jointly develop expanded test content both within NIPT and beyond.

Premaitha is headquartered in Manchester, England, with Yourgene offices in Taipei and Singapore. Its shares trade on the AIM market of the London Stock Exchange (AIM: NIPT). For further information, please visit www.premaitha.com. Follow us on twitter @PremaithaHealth.

  • 12 July 2017 - Investment Agreement Extension with Thermo Fisher Scientific +

    Premaitha Health Plc
    (“Premaitha”, the “Company” or the “Group”)

    Investment Agreement Extension with Thermo Fisher Scientific

    Manchester, UK – 12 July 2017 - Premaitha Health Plc (AIM: NIPT), a leading international molecular diagnostics group focused on non-invasive prenatal testing, is pleased to announce that it has entered into a further extension of the investment agreement with Thermo Fisher Scientific (“Thermo Fisher”) announced on 14 December 2015 and extended as announced on 23 September 2016, further developing

    Read More
  • 10 July 2017 - Premaitha announces two laboratory hub contracts in South East Asia +

    Premaitha Health plc
    (“Premaitha” or the “Company” or the “Group”)

    Premaitha announces two laboratory hub contracts in South East Asia

    Manchester, UK – 10 July 2017: Premaitha Health plc (AIM: NIPT), a leading international molecular diagnostics group focused on non-invasive prenatal testing (“NIPT”), announces that it has signed contracts with two significant laboratories in South East Asia through its Taiwanese subsidiary, Yourgene Bioscience (“Yourgene”).

    The agreements have been signed with two partners for laboratories which

    Read More
  • 3 July 2017 - Litigation Update +

    Premaitha Health PLC
    (“Premaitha” or the “Company”)

    Litigation Update

    Manchester, UK – 3 July 2017: Premaitha Health PLC (AIM: NIPT), a leading international molecular diagnostics group focused on non-invasive prenatal testing (“NIPT”), provides the following update on the legal proceedings in connection with patent infringement suits filed by Illumina, Inc. and others (together the “Claimants”). The patents in issue in these proceedings fall into three families: European Patent (UK) 0 994 963; European Patent (UK)

    Read More
  • 26 June 2017 - The IONA® test updated to include the first trimester combined test result +

    Premaitha Health PLC
    (“Premaitha” or the “Company”)

    The IONA ® test updated to include the first trimester combined test result

    Manchester, UK – 26 June 2017: Premaitha Health, a leading international molecular diagnostics group focused on non-invasive prenatal testing (“NIPT”), is pleased to announce enhancements to the IONA ® test, which now incorporates the first trimester combined test risk score into its software.

    The IONA ® test is Premaitha’s leading CE-marked non-invasive prenatal test which

    Read More
  • 16 June 2017 - Premaitha launches Sage™ prenatal screening solution in Hong Kong +

    Premaitha Health PLC
    (“Premaitha” or the “Company”)

    Premaitha launches Sage™ prenatal screening solution in Hong Kong

    Manchester, UK – 16 June 2017: Premaitha Health PLC (AIM: NIPT), a leading international molecular diagnostics group focused on non-invasive prenatal testing (“NIPT”), announces the launch of Sage™, an NIPT solution incorporating additional prenatal screening analysis tools.

    Sage™ is an advanced NIPT analysis solution, available through Yourgene Bioscience Singapore (“Yourgene”), which was acquired by Premaitha in March 2017. It

    Read More
  • 5 June 2017 - India Business Update +

    Premaitha Health plc
    (“Premaitha” or the “Company” or the “Group”)

    India Business Update

    Manchester, UK – 5 June 2017: Premaitha Health plc (AIM: NIPT), a leading international molecular diagnostics group focused on non-invasive prenatal testing, is pleased to provide an update on commercial progress in India.

    Yourgene Bioscience (“Yourgene”), acquired by Premaitha in March 2017, is now firmly established as one of India’s leading providers in the emerging non-invasive prenatal testing (“NIPT”) market,  with representation

    Read More
  • 26 May 2017 - Premaitha completes IONA test validation on Thermo Fisher’s Ion S5 instrument +

    Premaitha Health PLC
    (“Premaitha” or the “Company”)
     
    Premaitha completes IONA test validation on Thermo Fisher’s Ion S5 instrument
     
    Manchester, UK – 26 May 2017: Premaitha Health plc (AIM: NIPT, “Premaitha” or the “Company”), a leading international molecular diagnostics group focused on prenatal testing, announces that the IONA ® test, the Company’s CE-IVD non-invasive prenatal test (“NIPT”), has been validated for use on Thermo Fisher Scientific’s Ion S5 range of instruments.
     
    The validation
    Read More
  • 19 May 2017 - Premaitha welcomes NIPT recommendation in France +

    Premaitha Health PLC
    (“Premaitha” or the “Company”)
     
    Premaitha welcomes NIPT recommendation in France
     
    Haute Authorité de Santé recommends introduction of NIPT for high and intermediate risk women
     
    Manchester, UK – 19 May 2017: Premaitha Health plc (AIM: NIPT, “Premaitha” or the “Company”), a leading international molecular diagnostics group focused on prenatal testing, welcomes the recommendation by the Haute Authorité de Santé (“HAS”), the French National Authority for Health, to make non-invasive prenatal
    Read More
  • 12 May 2017 - Update Re. Swiss Customer +

    Premaitha Health PLC
    (“Premaitha” or the “Company”)

    Update Re. Swiss Customer

    Manchester, UK – 12 May 2017: Premaitha Health plc (AIM: NIPT, “Premaitha” or the “Company”), a leading international molecular diagnostics group focused on prenatal testing, announces that the Company’s application for its Swiss customer, Genoma SA (“Genoma”), to be placed into bankruptcy for non-payment of debts has been successful (the “Ruling”).

    As previously announced in the Company’s interim results (see RNS announcement on 21

    Read More
  • 13 March 2017 - Premaitha Raises Awareness of the IONA® Test at Key International Medical Events +

    Premaitha Health PLC
    (“Premaitha” or the “Company”)

    Premaitha Raises Awareness of the IONA ® Test at Key International Medical Events

    Manchester, UK – 13 March 2017: Premaitha Health PLC (AIM: NIPT), a leading international molecular diagnostics group focused on prenatal testing, will be attending a series of key international fetal medicine and OB/GYN events during March to broaden awareness of the IONA ® test. The events will include:

    The Royal College of Obstetricians and Gynaecologists

    Read More
  • 1
  • 2
  • 3
  • 4
  • 5
  • 6
  • 7
Pregnant lady sitting at table with Laptop

Investor Relations
Ben Simons / Fiona Henson
Vigo Communications
180 Piccadilly
London W1J 9HF
premaitha@vigocomms.com
T : +44 (0) 20 7830 9700

Two business people looking at computer screen